PITTSBURGH (AP) - Mylan has begun selling generic versions of the allergy drug Clarinex and also the bipolar disorder treatment Lithobid.
The products started shipping after approval was granted by the Food and Drug Administration approval, the generics company said. The FDA approval covered 5 milligram tablets of Clarinex, or desloratadine, and 300 milligram tablets of Lithobid, or lithium carbonate. Lithobid is used as a maintenance treatment for bipolar disorder and as a treatment for manic episodes associated with bipolar disorder.
Clarinex is made by Merck & Co., and Mylan said U.S. sales totaled $194.6 million over the 12 months ended March 31. Noven Therapeutics makes Lithobid, and Mylan said U.S. sales were $21 million over the 12-month period ended March 31.
Date: July 3, 2012
Source: Associated Press